Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Jun Araki, Isamu Okamoto, Ryuichiro Suto, Yasuko Ichikawa, Ji Ichiro Sasaki

研究成果: Contribution to journalArticle査読

39 被引用数 (Scopus)

抄録

Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

本文言語英語
ページ(範囲)141-144
ページ数4
ジャーナルLung Cancer
48
1
DOI
出版ステータス出版済み - 4 2005
外部発表はい

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

フィンガープリント 「Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル